STOCK TITAN

Checkpoint Therapeutics, Inc. - $CKPT STOCK NEWS

Welcome to our dedicated page for Checkpoint Therapeutics news (Ticker: $CKPT), a resource for investors and traders seeking the latest updates and insights on Checkpoint Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Checkpoint Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Checkpoint Therapeutics's position in the market.

Rhea-AI Summary
Checkpoint Therapeutics, Inc. announced the immediate exercise of certain outstanding warrants, expected to generate approximately $11.13 million in gross proceeds. The funds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.29%
Tags
none
-
Rhea-AI Summary
Checkpoint Therapeutics to participate in Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
conferences
-
Rhea-AI Summary
Checkpoint Therapeutics to present corporate overview at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
conferences
Rhea-AI Summary
Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) announced that the U.S. FDA is reviewing the Biologics License Application for cosibelimab, with a PDUFA goal date of January 3, 2024. Longer-term results demonstrate substantial increases in complete response rates and continued favorable safety profile in advanced cutaneous squamous cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
-
Rhea-AI Summary
Checkpoint Therapeutics announces a registered direct offering of its common stock and warrants, with gross proceeds expected to be approximately $10 million. The funds will be used for working capital, general corporate purposes, and pre-commercial activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.45%
Tags
-
Rhea-AI Summary
Checkpoint Therapeutics announces new data for cosibelimab in locally advanced and metastatic cSCC, showing increased complete response rates over time. The drug also demonstrates a favorable safety profile. The Biologics License Application is under review by the FDA with a goal date of January 3, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.15%
Tags
none
Rhea-AI Summary
Checkpoint Therapeutics presents new pharmacokinetic data on cosibelimab at the PAGE 2023 annual meeting. Results support comparability of dosing regimens. Biologics License Application for cosibelimab under FDA review with a PDUFA goal date of January 3, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
-
Rhea-AI Summary
Checkpoint Therapeutics announced that the FDA has accepted the filing of the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma. The Prescription Drug User Fee Act goal date is set for January 3, 2024. Checkpoint also reported financial results for Q1 2023, including a decrease in cash position and an increase in research and development expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.84%
Tags
Checkpoint Therapeutics, Inc.

Nasdaq:CKPT

CKPT Rankings

CKPT Stock Data

57.49M
28.74M
7.87%
14.53%
10.48%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WALTHAM

About CKPT

checkpoint therapeutics, inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. the company's product candidates include ck-101 that in phase i clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and cosibelimab, a programmed death ligand-1 (pd-l1), which is in phase i clinical trial in patients with selected recurrent or metastatic cancers. it also develops ck-103, a small molecule inhibitor of bet bromodomains; and ck-302, a human agonistic antibody for oncology indications. checkpoint therapeutics, inc. has collaboration agreements with tg therapeutics, inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. the company was founded in 2014 and is headquartered in new york, new york. checkpoint therapeutics, inc. is a subsidiary of fortr